6 Amendments of Andrey NOVAKOV related to 2019/2073(DEC)
Amendment 2 #
Proposal for a decision 1
Paragraph 1
Paragraph 1
1. Grants the Executive Director of the European Medicines Agency discharge in respect of the implementation of the Agency’s budget for the financial year 2018/ Postpones its decision on granting the Director of the European Medicines Agency discharge in respect of the implementation of the Agency’s budget for the financial year 2018;
Amendment 3 #
1. Approves the closure of the accounts of the European Medicines Agency for the financial year 2018/ Postpones the closure of the accounts of the European Medicines Agency for the financial year 2018;
Amendment 6 #
Motion for a resolution
Paragraph 3
Paragraph 3
3. Notes with concern that EudraVigilance, an information system used to report suspected side effects of medicines, and other telematics projects had to be postponed or reduced due to the United Kingdom’s decision to withdraw from the European Union; however, acknowledges that the Agency reassures that the projects and activities under the Brexit Business Continuity Plan (BCP) were carried out in a way which did not affect the functioning of the safety monitoring system for medicines in the Union and allowed all parties involved (industry, the Agency, national competent authorities) to continue complying with their legal obligations under the Union pharmaceutical legislation;
Amendment 16 #
Motion for a resolution
Paragraph 14
Paragraph 14
14. Notes that the Agency meets with lobbyistinterest representatives and has rules in place to govern its interactions with stakeholders, and furthermore that it continues to publish the minutes of meetings with interest representatives on its website; notes that the Agency continues to implement a framework for stakeholder relation management, in consultation with the Commission, which encompasses transparency measures;
Amendment 21 #
Motion for a resolution
Paragraph 17
Paragraph 17
17. Notes that the Court issued an emphasis of matter paragraph in relation to the two London-based agencies, concerning the United Kingdom’s decision to withdraw from the European Union; notes that the seat of the Agency moved to Amsterdam in March 2019 and that the Agency’s accounts at 31 December 2018, included provisions for related costs amounting to EUR 17 800 000; regrets that the lease agreement for the London based premises sets a rental period until 2039 with no exit clause; also regrets that on 20 February 2019, the High Court of Justice of England and Wales ruled against EMA’s request to cancel the lease; notes, however, that the lease agreement allows reassignment or subletting of the premises to third parties, subject to the landlord’s consent; deeply regrets that the notes to the accounts at 31 December 2018 disclosed an amount of EUR 468 000 000 remaining rent until 2039, of which an amount of EUR 465 000 000 for the lease period after the Agency’s planned move to Amsterdam is disclosed as a contingent liability; urges the Commission together with the Agency to do itstheir utmost to minimise the financial, administrative and operational impact of the unfavourable lease agreement and to report to the discharge authority on the developments in this regard;
Amendment 24 #
Motion for a resolution
Paragraph 19
Paragraph 19